Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Palliative Care 2Nivolumab 2Methods 2Ipilimumab 2CTLA-4 Antigen 2Biopsy 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1pembrolizumab 1peginterferon alfa-2a 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × bintrafusp alfa protein, human × Other hematologic neoplasm × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡